Researchers in South Africa and Brazil have initiated clinical trials to assess a Covid-19 vaccine candidate, ChAdOx1 nCoV-19 (AZD1222), developed by the University of Oxford and licensed to AstraZeneca.

Sponsored by Lemann Foundation, the trial in Brazil will assess the vaccine candidate in 2,000 health workers in Sao Paulo and 1,000 people in Rio de Janeiro.

Brazil’s health regulator Anvisa approved trials of the vaccine earlier this month. Researchers expect to launch the Covid-19 vaccine by the end of this year.

Meanwhile, the University of Witwatersrand in South Africa is working with the University of Oxford and the Oxford Vaccine Group to evaluate the vaccine candidate. This marks South Africa’s first trial of a vaccine against Covid-19.

Named Ox1Cov-19 Vaccine VIDA-Trial, the South African study will be led by Witwatersrand University vaccinology professor Shabir Madhi. The trial will be performed at several sites across South Africa.

The South African Health Products Regulatory Authority (SAHPRA) and the University of the Witwatersrand’s Human Research Ethics Committee approved the study.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Madhi noted: “This is a landmark moment for South Africa and Africa at this stage of the Covid-19 pandemic. As we enter winter in South Africa and pressure increases on public hospitals, now more than ever we need a vaccine to prevent infection by Covid-19.”

Screening of participants for the South African Oxford Covid-19 vaccine study commenced last week and the first participants are set to be vaccinated this week.

The vaccine candidate is made from ChAdOx1 virus, which is a weakened and non-replicating version of a common cold virus called adenovirus. Created at the Oxford University’s Oxford Jenner Institute, the vaccine has been engineered to express the SARS-CoV-2 spike protein.

Following vaccination, the human body is expected to identify and develop an immune response to the spike glycoprotein, in turn blocking the entry of SARS-CoV-2 virus into human cells.

In the UK, the vaccine’s trial has already enrolled more than 4,000 participants, with plans to enrol an additional 10,000 volunteers.